Zai Lab (NASDAQ:ZLAB) was upgraded by equities researchers at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a research note issued on Wednesday, MarketBeat reports. The firm presently has a $32.00 price objective on the stock. JPMorgan Chase & Co.’s price objective suggests a potential upside of 32.12% from the company’s previous close.
Separately, BidaskClub raised Zai Lab from a “sell” rating to a “hold” rating in a research note on Wednesday, January 31st.
Zai Lab (ZLAB) traded up $2.22 on Wednesday, hitting $24.22. The stock had a trading volume of 214,548 shares, compared to its average volume of 84,902. Zai Lab has a 12 month low of $19.80 and a 12 month high of $35.74.
TRADEMARK VIOLATION NOTICE: “Zai Lab (ZLAB) Upgraded by JPMorgan Chase & Co. to Overweight” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/14/zai-lab-zlab-upgraded-by-jpmorgan-chase-co-to-overweight.html.
Zai Lab Company Profile
Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases.
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.